Contineum Therapeutics, Inc. Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares
Contineum Therapeutics, Inc. (CTNM) reported Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares of 0 shares for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares · last filed 2025-03-06
- Contineum Therapeutics, Inc. incremental common shares attributable to dilutive effect of contingently issuable shares for fiscal 2024 was 0.00 shares, a 100.00% decline from fiscal 2023.
- Contineum Therapeutics, Inc. incremental common shares attributable to dilutive effect of contingently issuable shares for fiscal 2023 was 4.14K shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares 12 month |
|---|---|
| 2024-12-31 | 0.00 shares 10-K · filed 2025-03-06 |
| 2023-12-31 | 4.14K shares 10-K · filed 2025-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |